From GlobeNewswire: 2025-03-18 07:30:00

MiNK Therapeutics announced its financial results for Q4 and full year 2024, highlighting clinical advancements in iNKT cell therapies for cancer and immune-related disorders. The company also showcased operational highlights, next-generation iNKT programs, growth initiatives, and financial metrics. MiNK’s cutting-edge manufacturing process and strategic collaborations position it for continued success in 2025.

Operational highlights include significant advancements in cancer treatment with AgenT-797, showing enhanced immune activation and efficacy. Promising results were also seen in inflammatory lung conditions. MiNK is progressing next-generation iNKT programs like PRAME-TCR iNKTs and MiNK-215, showing potent anti-tumor activity in various models. These advancements underscore MiNK’s commitment to pioneering innovative cancer treatments.

MiNK’s strategic growth initiatives and manufacturing optimization enable the production of billions of iNKT cells per run. The company has entered into a research collaboration with Autonomous Therapeutics to develop precision RNA-iNKT therapies for metastatic tumors. With $5.8M raised in private financing, MiNK is focused on externally funded clinical trials to advance its iNKT cell programs effectively.

Financially, MiNK ended 2024 with a cash balance of $4.6 million, with cash used in operations totaling $1.7 million and $9.6 million for the three and twelve months ended December 31, 2024, respectively. The net loss for 2024 was $10.8 million, compared to $22.5 million in 2023. Key financial metrics and consolidated balance sheet data were also provided in the report.

MiNK Therapeutics is set to host a conference call and webcast to discuss its financial results and operational updates. Interested parties can join the conference call using the provided dial-in numbers. The webcast will be accessible from the Company’s website for further information on MiNK’s advancements in iNKT cell therapies and strategic collaborations. Investors and stakeholders can stay informed through MiNK’s website and social media channels for important updates.

AgenT-797, an allogeneic iNKT cell therapy developed by MiNK Therapeutics in Lexington, MA, harnesses the power of innate and adaptive immunity to combat hard-to-treat tumors. Clinical trials have shown its potential to enhance T-cell activation and improve outcomes for cancer patients. Forward-looking statements caution investors about the risks and uncertainties associated with iNKT cell therapies and collaborations. For further information, investors can reach out to MiNK’s investor and media contacts provided in the press release.



Read more at GlobeNewswire:: MiNK Therapeutics Reports Fourth Quarter & Full Year 2024